Imatinib Cipla

Imatinib, the active ingredient in Imatinib Cipla, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients and works by targeting specific cellular pathways that drive malignant cell growth.

GNH USA supplies Imatinib Cipla as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on abnormal tyrosine‑kinase pathways that drive certain cancers.

- Chronic myeloid leukemia: reduces disease progression, improves hematologic and cytogenetic response, and extends survival. - Gastrointestinal stromal tumor: inhibits tumor growth and delays disease progression in patients with KIT or PDGFRA mutations. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: contributes to remission induction and maintenance therapy. - Other BCR‑ABL positive neoplasms: provides disease control in selected hematologic malignancies.

Adverse reactions may occur with imatinib therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or face. - Fatigue: persistent tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing heart disease.

Before initiating therapy, clinicians should assess patient‑specific factors.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: baseline ECG for patients with cardiac risk. - Avoid in severe hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several concomitant medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase imatinib exposure. - Warfarin: may enhance anticoagulant effect and raise INR. - Cimetidine: can raise plasma levels of imatinib.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce imatinib effectiveness. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously. - Diuretics (e.g., furosemide): increase risk of hypokalemia when combined with imatinib.